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Food-specific sublingual immunotherapy
is well tolerated and safe in healthy dogs:
a blind, randomized, placebo-controlled
study
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Abstract
Background: Food allergies are increasing in prevalence but no treatment strategies are currently available to
cure dogs with food allergy. Over the past decade, experimental food allergen-specific sublingual immunotherapy
(FA-SLIT) has emerged as a potential treatment for food allergies in human medicine. However, FA-SLIT has not
been investigated in dogs. Therefore, the objective of this study was to prospectively evaluate the safety, tolerability
and dispenser sterility of FA-SLIT in healthy dogs before testing it in food allergic dogs.
Eight experimental healthy beagle dogs, never orally exposed to peanut, were randomized in two groups to
receive SLIT with peanut or placebo for 4 months. Subjects were monitored daily for local and systemic adverse
effects. Blood samples for complete blood count and serum biochemistry, and urine for urinalysis were collected
and the dogs’ body weight was recorded at day 0, 35 and 119 of the SLIT treatment. Sera for the determination of
peanut-specific IgG and IgE were collected at day 0, 35, 49, 70, 91, 105 and 119. Intradermal tests were performed
before (day 0) and after (day 119) the experiment. The content of each dispenser used to administer treatment or
placebo was tested for sterility after usage. In order to assess the presence or absence of sensitization, dogs were
challenged 6 months after the end of the study with 2000 μg of peanut extract daily for 7 to 14 days.
Results: All dogs completed the study. The treatment did not provoke either local or systemic side-effects. Peanut-
specific IgG significantly increased in treatment group. Even though a significant increase in peanut-specific IgE
was also seen, intradermal tests were negative in all dogs before and after the experiment, and the challenge test
did not trigger any adverse reactions in the treated dogs, which shows the protocol did not cause sensitization to
peanut, but nevertheless primed the immune system as indicated by the humoral immune response. All dispenser
solutions were sterile.
Conclusions: Our results demonstrate that the used peanut-SLIT protocol is well tolerated and safe in healthy dogs.
Further studies should evaluate tolerability, safety and efficacy in dogs with food allergy.
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Background
Food allergy is a relatively rare but progressive problem
in both humans and dogs [1–5].
The treatment involves strict avoidance of allergen-
intake and, if necessary, it is combined with symptom-
atic therapy. However, it is not possible to cure food
allergy in dogs. Researchers have shown that allergen-
specific immunotherapy may be a potentially curative
treatment for food allergy in humans [6–8]. Immunother-
apy entails frequent contact with the specific allergen,
starting from a low dose that gradually increases. This
leads to a modification of the immune response, with an
increased threshold value at which clinical symptoms
occur.
In humans, different approaches exist according to
the route of administration: subcutaneous immunother-
apy (SCIT), oral immunotherapy (OIT), sublingual
immunotherapy (SLIT) and only recently epicutaneous
immunotherapy (EPIT). Although SCIT has been suc-
cessfully used in the treatment of patients with atopic
dermatitis, its use in food allergy is dissuaded because
of high risk for severe side effects such as itching, urti-
caria, angioedema and symptomatic bronchoconstric-
tion [9]. To overcome these problems, OIT and SLIT
have been used [10]. The former comprises the daily
consumption of milligrams to grams of allergen in a
food vehicle. The latter involves dispensing small
amounts (micrograms to milligrams) of allergen extract
under the tongue. Both these therapeutic approaches
provide progressively increasing amounts of allergen,
over weeks to months, until an established maintenance
dose is reached. Adverse events consisting of multisystem,
upper and lower respiratory tract and gastrointestinal
symptoms, are reported for both routes of administration;
however, in humans, the safety profile of SLIT seems
superior to this of OIT [11]. Oropharyngeal itching is the
most common SLIT-related side effect, which typically
occurs during the build-up phase and mostly resolves
without any treatment. Systemic side effects are very rare.
Studies examining SLIT for specific food in humans are
limited to hazelnut [12], peanut [6, 13], cow’s milk [14],
peach [15] and kiwi [16]. The aims of SLIT are to achieve
desensitization by increasing the threshold for clinical
reactivity to the culprit food and later to induce/restore
tolerance induction, which refers to the ability to ingest
the food without allergic reaction after discontinuation
of the therapy. Thus far, available evidence suggests
that SLIT is able to induce desensitization in the major-
ity of patients (between 52 and 100% of treated patients)
with only one study reporting a lower percentage (10%)
[6, 11–15]. Only one study evaluated the capacity of SLIT
to induce tolerance between 10 and 50% of patients [11].
In contrast to the extensive literature describing the use of
immunotherapy in humans with food allergy, no studies
have been performed in dogs. Therefore, the purpose of
this study was to evaluate the safety, tolerability and
dispenser sterility of SLIT with peanut allergen in a pro-
spective, randomized, blinded, controlled study in healthy
dogs.
Methods
Study design
The study was approved by the Ethical Committee of the
University of Ghent, Belgium (EC 2014/144 (experiment)
EC 2014/121 (Intradermal test)).
This study was a randomized, blinded, placebo-controlled
study using escalating doses of peanut extract in healthy
dogs.
Randomization and blinding procedures
Subjects were allocated to a treatment group or
placebo group (four dogs per group), following simple
randomization by flipping a coin: the side of the coin
(heads or tails) determined the assignment of each
subject. Ten equally looking dispensers were prepared
by the principal investigator during the experiment.
Five dispensers, named Group 1 and numbered from 1
to 5, contained different concentrations peanut extract
solution, and five others (named Group 2 and also
numbered from 1 to 5) contained only placebo, as de-
scribed further. A second investigator, responsible for
administering the solution to the dogs, and the animal
care takers were blinded to the treatments.
Animals
Eight clinically healthy laboratory raised beagle dogs
were included: four intact females, one neutered female,
one intact male and two spayed males. Median age was
6,25 years (±3,15 SD) (range 2–10 years) and median
weight 10,5 (± 1,44 SD) (range 8,2–12,3 kg) (Table 1).
To our knowledge all subjects never received peanut
in their diet. Clinical histories were evaluated and the
dogs underwent an accurate clinical examination to rule
Table 1 Signalment and assigned group of eight beagles dogs
included in the study (Day 0)
Group No. Sex Age (years) Weight (kg)
P 1 MC 9 9,8
P 2 M 10 8,2
P 3 MC 3 10,2
P 5 F 7 10,1
T 4 F 7 12,3
T 6 FS 3 12,3
T 7 F 9 11,7
T 8 F 2 9,7
Abbreviations: F intact female, FS female spayed, M male, MC male castrated,
P placebo group, T treatment group
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out presence of allergy or other diseases, before the
inclusion.
Housing
Dogs were housed in kennels in a research facility at the
Faculty of Veterinary Medicine, Ghent University. Each
kennel consisted of an inner portion (90 cm × 473 cm)
and an outer part (90 cm × 300 cm). All dogs had their
own equipment (e.g toys and bowls) and the animal care
takers were properly trained not to mix these materials
among dogs.
Peanut and placebo sublingual drops
The treatment group received lyophilized peanut extract
(Greer®, Lenoir, NC, USA) fully dissolved in 50% glycerin-
ated saline to a maximum peanut protein concentration of
20,000 μg/ml. Normal sterile glycerinated saline solution
served as placebo. Both solutions (peanut extract and the
placebo solutions) were poured into dark dispensers. As
described previously, 5 dispensers per group (numbered
from 1 to 5) were prepared. All dispensers addressed to
the placebo group contained only sterile glycerinated
saline solution. Dispensers for the treatment group
contained increasing concentrations of peanut extract
solution with number 1 being the least concentrated
(Table 2). Dilutions were made with glycerinated saline
under sterile conditions. Peanut extracts and dispensers
containing placebo or treatment solutions were kept at
4 °C during the study period.
SLIT protocol
Before and during the study, dogs were fed a strict
peanut-free diet. The solution was administered sublin-
gually, by hooking a dispenser tip over the lower teeth
and dispensing from 50 to 250 μl (1 push dispensed
50 μl) of solution into the oral cavity under the tongue.
This was performed once a day at the same time for all
dogs, at least 1 hour after the meal (Fig. 1). Dogs were
not allowed to eat and drink for 30 min after peanut or
placebo administration. After each administration, the
oral cavity of the dogs was carefully examined to rule
out accidental injuries by the dispenser. After the start-
ing dose of 0.25 μg peanut protein, doses were in-
creased on day 2 and again on day 3. Then weekly
increases by 25 to 100% occurred until the daily main-
tenance dose of 2000 μg peanut protein was reached
(Table 2). This maintenance dose was continued daily
for 2 months. Subjects were monitored, by the primary
investigator, several times during the hour following
each administration. After each dose increase and the
subsequent day dogs were monitored for an additional
2 h in the morning and 2 h in the evening to moni-
tor onset of pruritus which could have been masked
by the dogs’ excitement during the short daily visits.
Furthermore, animal caretakers were also instructed to
monitor on a daily basis for adverse effects (e.g. vomiting,
diarrhoea, urticaria, angioedema and oral pruritus) and to
record it.
Tolerability assessments
Definition
Tolerability is referred to as absence of SLIT-related local
adverse events.
Clinical evaluation
The muzzle, mouth and the oral cavity of the dogs were
examined in detail by the principal investigator. All
changes observed after the first visit (day 0) (e.g. erythema,
swelling, vesicles and ulcerations, immediate or delayed
oral or muzzle itching, sialorrhea, continuous chewing
and vomiting) were recorded and the possible relation
Table 2 Peanut SLIT dosing schedule for the treatment group
Week Days Dilutions Dispenser n° Pumpsa Protein (μg)
1
1 1:4000 1 1 0.25
2 1:4000 1 5 1.25
3 1:400 2 1 2.5
4 1:400 2 1 2.5
5 1:400 2 1 2.5
6 1:400 2 1 2.5
7 1:400 2 1 2.5
2 1:400 2 2 5
3 1:400 2 4 10
4 1:40 3 1 25
5 1:40 3 2 50
6 1:40 3 4 100
7 1:4 4 1 250
8 1:4 4 2 500
9 1:1 5 1 1000
10 1:1 5 2 2000
11 1:1 5 2 2000
12 1:1 5 2 2000
13 1:1 5 2 2000
14 1:1 5 2 2000
15 1:1 5 2 2000
16 1:1 5 2 2000
17 1:1 5 2 2000
Five dispensers (1–5) with increasing concentrations were used as well as variable
number of pumps to come to increasing amounts of protein administered
sublingually. The amount of protein dispensed ranged from 0,25 μg to 2000 μg.
Placebo (only glycerinated solution was administered) was administered
according to the same protocol
aEach pump dispensed 50 μl of solution
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with the treatment was assessed by the Naranjo adverse
drug reaction probability scale [17].
Safety assessments
Definition
Safety refers to SLIT-related reactions that occur far from
the site of administration and include both life-threatening
and nonlife-threatening systemic adverse events [18].
Clinical adverse events and concomitant medications
administered
All observed adverse events that occurred during the
study period or within 14 days after the end of the
experiment were recorded (e.g. diarrhoea, abdominal
pain, urinary tract infection/cystitis, facial urticaria,
erythema and pruritus on the axillae, groins paws and
perianal area, pyoderma, otitis, epilepsy, somnolence,
anorexia and anaphylaxis). Onset, duration, severity
and treatments were noted. Naranjo Adverse Drug
Reaction Probability Scale was used to assess the likeli-
hood of a real adverse drug reaction [17].
Clinical laboratory tests
Complete blood count analysis was performed before
and at the end of the experiment. Blood samples for
serum chemistry, and urine for urinalysis (free catch)
were collected just before the first administration at day
0, also at day 35 and again at day 119, the end of SLIT.
Hepatic functions were evaluated by measurement of
alanine transferase (ALT), aspartate transferase (AST)
and alkaline phosphatase (ALP), and urinary functions
by determining creatinine, total protein and urea con-
centrations. Urinalysis was performed by urine dipstick
testing for pH, protein, glucose, bilirubin, specific grav-
ity, blood, ketones, nitrite, urobilinogen and ascorbic
acid.
Body weight change
Dogs were meticulously weighted during each visit. Any
change in the body weight (BW) was recorded.
Intradermal test
Intradermal testing was performed at the end of SLIT,
day 119, by intradermal injection of 20 μg peanut pro-
tein (0.05 ml of a 1:1000 w/v dilution of peanut protein)
in the ventral lateral area of the abdomen. The wheals
induced were measured after 15 min, 24 h, 48 h and
72 h. Saline solution was used as a negative control and
a dilution 1:10 of histamine phosphate (0275 mg/mL)
(Greer Laboratoires, Lenoir, NC, USA) was used as posi-
tive control. Peanut extract and histamine were diluted
with saline solution.
Challenge testing
In order to assess late occurring sensitization, the four
treated dogs were challenged 6 months after the end of
the study with sublingual administration of 2000 μg of
peanut extract daily for 7 days and in one dog challenge
Fig. 1 SLIT administration in a dog. Dispenser tip is hooked over the lower teeth, into the oral cavity, under the tongue a, b. A drop of solution is
then dispensed by pushing the cap of the dispenser c, d
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was even prolonged for a week. All dogs were monitored
for 14 days. Onset of pruritus or any other clinical signs
were recorded.
Tolerance induction assessment
Peanut-specific IgG and IgE enzyme-linked immunosorbent
assay (ELISA)
To probe the induction of suppressive IgG antibodies ra-
ther than potentially sensitizing IgE antibodies in subjects
undergoing peanut-specific SLIT, the peanut-specific IgG
and IgE responses were analysed.
Sera were obtained from all dogs (active and placebo) at
day 0, 35, 49, 70, 91, 105 and 119 of the SLIT treatment
and then frozen at -20 °C until processed. Circulating con-
centrations of peanut-specific IgG and IgE were deter-
mined by ELISA. Briefly: Nunc MaxiSorp® flat-bottom 96-
well plates were coated overnight at 4 °C with solutions of
the peanut protein at 0.05 mg/ml in bicarbonate buffer,
whereafter they were blocked at room temperature with
2% gelatine from cold fish water skin (Sigma-Aldrich®,
Steinheim, Germany) in bicarbonate buffer. In subsequent
steps performed at room temperature, wells were first
incubated with serum samples (diluted 1/2.5 and 1/50 for
IgE and IgG respectively) for 2 hours, then with polyclonal
goat anti-canine heavy and light chain IgG (125 ng/ml)
(Bethyl, Montgomery, USA, A40-123P) or polyclonal goat
anti-canine IgE (125 ng/ml) (Novus Biologicals, Cam-
bridge, UK, NB7346) HRP-conjugated antibodies for 1 hour
and finally with a solution of ABTS (Roche Diagnostics,
Mannheim, Germany). The OD was measured at 405 nm
(Tecan Spectra Fluor Fluorescence and Absorbance
Reader) and analyzed with the XFluor™ software. In be-
tween steps, plates were washed from three to five times,
using 0,05% Tween®20 in PBS. Sera and antibodies were di-
luted in bicarbonate buffer with 2% gelatine from cold
water fish skin.
Sterility testing at the final container
The sterility testing was performed following the method
described in the fifth Edition of the International
Pharmacopoeia (http://apps.who.int/phint/pdf/b/Jb.7.3.2.
pdf ). Briefly, before and after first using all dispensers
(placebo and treatment groups), 1 ml content was added
to 10 ml of Soybean-Casein Digest sterilized Medium
(Tryptone Soya Broth (TSB), Oxoid, Thermo scientific,
UK) and 1 ml to 10 ml of Nutrient broth (Nutrient Broth,
Difco, BD, USA). Dispenser 1 for both placebo and active
treatment was also tested at day 119 to evaluate the steril-
ity of its content overtime.
TSB was incubated at 22.5 °C and Nutrient Broth at
37 °C for 14 days. Cultures were assessed daily. In case
of increased turbidity due to growth of potential con-
taminants such as fungal, yeast, aerobic and anaerobic
bacteria, further identification occurred.
Statistical analysis
Data were analysed with statistical software SPSS Statistics
21, (IBM, New York, United States). Haematological pa-
rameters, serum biochemistry and urinary parameters
(specific gravity and pH) were compared between
groups, before the experiment (day 0), at day 35 and at
the end of the SLIT (day 119). The data were subjected
to analysis of variance (ANOVA) in the context of gen-
eral linear models at a significance level of 0.05 [19].
Summary statistics (mean and SD) for BW and percent-
age change from baseline were calculated at each time
point. Significant differences in serum peanut-specific
IgG and IgE between the two groups were calculated
using a Mann-Withney U test. A p-value lower than
0.05 was considered significant.
Results
SLIT administration
All dogs completed the study. The administration of SLIT
was easy and well accepted by the dogs. The dispensers,
with their hooked nozzle, did not hurt their mucosa.
During and after administration of the solutions, the dogs
did not show any changes in their behaviour.
Tolerability assessments
Clinical evaluation
At the time of the inclusion, all dogs were healthy and
no lesions were noted on the skin and/or mucosae. All
dogs but one did not show any adverse effects during or
after the SLIT. Only one dog (placebo group) vomited
once during the induction phase. However, according to
the Naranjo scale, which estimates the probability of ad-
verse drug reactions, this case could be classified as a
‘doubtful’ reaction to one of the components of the pla-
cebo (Naranjo score -1).
Safety assessment
Clinical adverse events and concomitant medication
administered
No adverse effects were recorded and therefore no add-
itional treatment was given to the dogs during the study
period.
Laboratory tests
Administration of peanut-specific immunotherapy had
no significant effect on haematology, on indices of hep-
atic and renal functions nor on urinalysis between
groups and over time. The values for all these parame-
ters were within the normal laboratory reference ranges
for each analyte at all time points, showing that they
were not affected by the administration of either
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treatment or placebo (Table 3). Comparison between
groups did not show any significant difference.
Body weight changes
When compared with the baseline values (placebo
group: mean = 9,58 kg (± 0,93 SD); treatment group: =
11,5 kg (± 1,23 SD)), body weights remained relatively
constant during the study. The mean BW at the end of
the study was 9,58 kg (± 0,93 SD) in the placebo group
and 11,6 kg (± 1,11 SD) in the treatment group.
Intradermal challenge test
Intradermal testing of dogs with peanut extract at
the end of SLIT did not provoke any positive
reactions.
Sublingual challenge test
Sublingually challenging the treated dogs with peanut
extract 6 months after the end of the immunotherapy,
did not provoke any clinical signs.
Table 3 Complete blood count, serum chemistry, and urinary values (mean ± SD) and range for eight beagles dogs included in the
study at different time points
Parameters Mean ± SD Range
Day 0 Day 70 Day 119
P T P T P T
Complete blood count values
RBC 6,97 ± 0,72 6,39 ± 0,23 - - 7,39 ± 0,88 6,94 ± 0,04 6,20–8,70 milj/μl
Haematocrit 47,8 ± 5,56 44,33 ± 1,99 - - 47,45 ± 8,04 46,03 ± 1,66 43,0–59,0%
Haemoglobin 16 ± 2,21 14,88 ± 0,25 - - 16,68 ± 2,09 15,98 ± 0,49 14,0–20,0 g/dl
MCV 68,57 ± 1,96 69,38 ± 2,23 - - 63,95 ± 4,09 66,33 ± 2,12 63,0–77,0 fl
MCHC 33,37 ± 0,78 33,58 ± 1,55 - - 35,4 ± 2,05 34,7 ± 0,56 30,0–36,0 g/dl
%Reticulocyte 0,43 ± 0,15 0,35 ± 0,19 - - 0,78 ± 0,55 0,55 ± 0,33 2-0%
WBC 7556,67 ± 2091,28 7157,5 ± 1088,8 - - 6815 ± 2775,81 8180 ± 1047 6000–16000 /μl
Neutrophil 66,23 ± 7,83 68,68 ± 1,41 - - 62,88 ± 10,23 64,88 ± 4,84 55,0–77,0%
Lymphocyte 25,67 ± 6,13 20,98 ± 3,38 - - 22,23 ± 2,88 19,53 ± 2,31 12,0–35,0%
Monocyte 4,2 ± 0,75 4,23 ± 0,59 - - 6,75 ± 1,62 8,05 ± 1,23 0,0–10,0%
Eosinophil 3,17 ± 2,67 5,88 ± 3,52 - - 7,98 ± 13,04 7,28 ± 3,36 0,0–8,0%
Basophil 0,7 ± 0,26 0,15 ± 0,1 - - 0,18 ± 0,17 0,28 ± 0,15 0–1%
Platelet 395666,67 ± 137587,55 321500 ± 80172,73 - - 310500 ± 63321,93 248500 ± 29949,96 164000–510000
Biochemical values
Urea 2,35 ± 0,68 2,45 ± 1,05 3,2 ± 1,10 3,55 ± 1,95 2,7 ± 0,42 3,1 ± 1,70 2,5–9,6 mmol/L
Crea 28,5 ± 14,18 23,5 ± 8,54 32 ± 11,78 26 ± 9,80 24,5 ± 7,19 32 ± 28 44–159 mmol/L
ALT 24 ± 4,90 26,5 ± 5,26 33,5 ± 8,22 35 ± 8,25 10 ± 0 10 ± 0 10–100U/L
AST 11,5 ± 5 11,5 ± 5,97 13 ± 2,58 26 ± 10,95 13,5 ± 5 20 ± 7,48 0–50 U/L
ALP 108 ± 64,60 45 ± 6,63 132 ± 114,32 97 ± 43,50 122 ± 106,62 91,5 ± 69,19 23–212 U/L
Urinary values
SG 1018,75 ± 4,79 1018,75 ± 2,5 1017,5 ± 2,89 1018,75 ± 2,5 1017,5 ± 5 1018,75 ± 2,5 1015–1060
Proteins
(mg/dL)
Neg neg neg neg neg neg neg
Glucose
(mg/dL)
Neg neg neg neg neg neg neg
pH 6,13 ± 0,48 6125 ± 0,25 6125 ± 0,25 6125 ± 0,25 6,25 ± 2,89 6 ± 0 5,5–7,0
Blood Neg neg neg neg neg neg neg
Ketones Neg neg neg neg neg neg neg
Nitrite Neg neg neg neg neg neg neg
Urobilinogen Neg neg neg neg neg neg neg
Ascorbic acid Neg neg neg neg neg neg neg
Abbreviations: ALT alanine aminotransferase, ALP alkaline phosphatase, AST Aspartate transaminase, Crea creatinine, MCHC mean corpuscular hemoglobin
concentration, MCV Mean corpuscular volume, neg negative, P placebo group, RBC red blood cells, SG specific gravity, T treatment group, WBC white blood cells
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Tolerance induction assessment
Peanut-specific IgG ELISA
At day 105 and 119, the treatment group showed a signifi-
cant increase in peanut-specific serum IgG in comparison
to the placebo group (p = 0.0267 and 0.0369, respectively).
Although not significant at all time points, starting from
day 70, the treatment group shows consistent higher
peanut-specific IgG concentrations in comparison to the
placebo group (Fig. 2).
Peanut-specific IgE ELISA
At day 91, 105 and 119, statistically significant differences
in peanut-specific IgE were seen when the treatment
group was compared to the placebo group (p = 0.0298,
0.00735 and 0.0245, respectively) (Fig. 3).
Sterility testing at the final container
None of the culture media developed turbidity after incu-
bation with 1 ml dispenser solutions, confirming the ster-
ility of the tested solutions (Fig. 4).
Discussion
This is the first prospective, randomized, blinded,
placebo-controlled trial of peanut-SLIT in dogs.
This study successfully demonstrated the safety and tol-
erability of the peanut-specific sublingual immunization in
healthy dogs: indeed, none of the dogs used in this study
experienced either systemic or local side effects.
Other studies that have been performed in humans
with different food extracts, including kiwi, hazelnut,
peach, cow’s milk and peanut, have shown that SLIT has
a very good safety profile [2, 8]. Most likely, testing dif-
ferent food extracts in dogs will lead to a similar
conclusion.
Side effects are rarely reported in human patients and
when present, they are mainly of local nature, such as
swelling and itching of the lips, inflammation of the area
under the tongue and the oropharynx, and often do not
require treatment [6, 13]. Skin itch is also reported, but
it was most commonly present in the placebo group [6].
Systemic reactions such as urticaria, angioedema and
asthma rarely occur. The occurrence of side effects is
mainly allergen and dose dependent and is mostly lim-
ited to the induction phase.
There are only few communications reporting the
safety of SLIT in dogs. A first pilot study investigated
the effect of SLIT in 10 mite-sensitive dogs with atopic
dermatitis [20]. This study was followed by a multicenter
open trial evaluating 124 dogs [21]. Although no side ef-
fects have been reported, it is worthwhile noting that
many dogs included in these studies received concurrent
medications in order to control symptoms or secondary
infections. Unfortunately, there are no studies about
food-specific sublingual immunotherapy in dogs. As the
avoidance of the offending factors is more difficult in
atopic dermatitis, it is clear that more efforts are done in
searching new treatments for atopic dermatitis than for
food allergy. In fact the prognosis for food allergy is gen-
erally good when the offending food allergen is identified
and the dog is fed with a diet in which this allergen is
absent. Strict avoidance of the offending allergen is ne-
cessary to avoid relapses. However, accidental reactions
are common, as allergens can be hidden in various
foods or contaminate commercial food [22]. Lack of
family member’s compliance and or the inappropriate
food access can lead to undesired relapses. The induc-
tion of tolerance against offending allergens might pre-
vent such relapses and as such be an important therapy
in food allergy. To be noted, while in humans one-third
of the people that strictly avoided the offending food
component for 1–2 years could tolerate it after such a
time span, in dogs natural desensitization rarely occurs
Fig. 2 Mean increase in OD for peanut-specific IgG in the treatment (white bars) and placebo groups (black bars) ± SD. SLIT ended at day 119.
Asterisk shows that at day 105 and 119, the increase in the treatment group was significant in comparison with the placebo group (p = 0.0267
and 0.0369, respectively)
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[23, 24]. Furthermore, even when the diet is strict,
dogs, as human, can become allergic to another food
component present in their diet after 2–3 years [25]. In
humans, the sensitization to other food, also called “al-
lergic cosensitization” or “collateral priming” has been
shown to be prevented through a T regulatory-cell-
dependent mechanism induced by an early allergen
specific immunotherapy [26–36]. Unfortunately, this
has not been assessed in dogs yet.
The goal of this study was to evaluate the safety and
the tolerability of food-specific sublingual immunization
in healthy dogs. Almost none of the dogs, in both the
placebo and treatment group, manifested any systemic
or local adverse effect. Only one dog in the placebo
group vomited once; however, there was no correlation
between placebo administration and clinical signs. Espe-
cially noteworthy is the extreme easiness of using pump-
type hooked-dispenser bottles which allowed a fast and
safe administration. In fact, we carefully examined the
oral cavity and no lesions were found. In addition, ab-
sence of changes in dog’s behaviour during the study
and in particular at the time of each administration, sug-
gests that the daily administration did not affect their
well-being. This is an important point which must not
be overlooked because, indirectly, it may increase the
compliance to treatment and consequently, also the effi-
cacy of the SLIT.
This study was limited to healthy dogs for two reasons:
first, since the main aim of this study is to evaluate the
safety of the protocol, it was necessary to use healthy
dogs in order to rule out irritation by the allergen used
rather than a real allergic reaction. Secondly, we wanted
to understand if this protocol could induce sensitization
against peanut allergen, this assessment would not have
been possible in dogs which were already allergic.
Peanut, Arachis hypogaea, was chosen because none
of the included dogs had previously eaten this protein
and because commercial diets for dogs normally do not
contain peanut as ingredient. We must emphasize that
even in case of induced allergy, the avoidance of this
protein would have been easier compared with other
proteins. The most striking aspect of this protein-choice
is that peanut causes the most severe and typically per-
manent hypersensitivity reactions to foods in humans,
and, therefore, it has been largely studied in human lit-
erature [37]. Currently, 17 proteins, namely, Ara h 1 to
Ara h 17, have been identified as peanut allergens
(WHO/IUIS Allergen Nomenclature Sub-Committee,
2015-07-07) [38]. These have been further classified as
major or minor allergens based on their ability to elicit
an IgE response in >90% of allergic patients [39]. Ara h1,
Ara h2, Ara h6 are known as major allergens and they
retain their IgE reactivity after heating and enzymatic di-
gestion, probably due to the stable and homotrimeric
structure, which protects the catalytic sites within the
protein [40–44].
Since the stability and potency of allergen extracts and
consequently the efficacy of the immunotherapy may be
affected by contamination, solutions and dispenser prep-
arations were made under sterile conditions [29–33].
Moreover, glycerin, which is a stabilizer and also preser-
vative, was added to allergen extract solutions to prevent
loss of allergens by sticking to the glass vials and to in-
hibit microbial growth.
No microorganisms could be cultured from the dis-
pensers’ content even 119 days after preparation and when
used for oral administration. Interestingly, the use of only
glycerin and no other preservatives such as phenol, which
is commonly used in vaccine preparations, is sufficient to
maintain the solution sterile. It should be borne in mind
that phenol, which is a good preservative, could dena-
turate allergens even when stabilised in 50% glycerine
[45–48].
It could be questioned that a four months sublingual
contact might not be enough to sensitize dogs. It is not
possible to estimate how long this study should need to
Fig. 3 Mean increase in OD for peanut-specific IgE in the treatment (white bars) and placebo groups (black bars) ± SD. Asterisk shows that at day 91,
105 and 119, the increase in the treatment group was significant in comparison with the placebo group (p = 0.0298, 0.00735 and 0.0245, respectively)
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have lasted to really exclude induction of allergy, as dogs
may develop food allergy spontaneously between the age
of 4 months to 14 years [49]. However, high concentra-
tions of food-specific IgE were already detected in 77,8%
and in 100% of the experimentally induced food allergic
beagles included in the study of Puigdemont et al. 2006,
respectively at day 57 and at day 85 of the sensitization
protocol, showing that sensitization can occur earlier. In
addition, food-specific intradermal testing was also posi-
tive in all sensitized dogs at day 85 [50]. Even though
the concentration of peanut-specific IgE was increased
significantly in our experiment, the intradermal test at
the end of the experiment and provocative diet challenge
were negative.
To note, a rise in IgE has also been demonstrated in hu-
man studies during the initial months of immunotherapy
and it does not lead to an increase in adverse reactions if a
simultaneous rise in allergen-specific IgG occurs [6, 51,
52]. Interestingly, in humans, as in our study, allergen-
specific IgG concentrations showed a simultaneous and
more extensive increase than IgE during therapy, suggest-
ing a good tolerance induction [6, 51, 52]. Indeed, there
are many articles reporting significant increase in serum
concentration of food-specific IgG and IgE after allergy
specific immunotherapy (ASIT). These increases have
been associated with successful oral and sublingual im-
munotherapy, desensitization and induction of tolerance
for specific food allergens. This has been extensively
Fig. 4 Sterility testing. Above: The content of all tubes was clear and no turbidity was seen after 14 days of incubation. Below: Magnifications of
the tubes inoculated with content of dispenser 1 showing no turbidity after incubation for 14 days as described in material and methods (from
left to right: Tryptone Soya Broth and peanut (*), Tryptone Soya Broth and placebo and only Tryptone Soya Broth (white arrow); Nutrient broth
and peanut (*), Nutrient broth and placebo, only Nutrient broth (black arrow))
Maina et al. BMC Veterinary Research  (2017) 13:25 Page 9 of 12
reported in human literature for both atopy and food
allergy and in veterinary literature only for canine
atopic dermatitis [6, 53–59]. Therefore, this is the first
article reporting an increase in serum concentration of
food-specific IgG after administration of a new protein
in naïve dogs. It is acknowledged that the skin test is
not a diagnostic assay for food allergy and the oral food
challenge (OFC) is still considered the gold standard
test. Therefore, we performed an OFC with 2000 μg of
peanut extract 6 months after the end of the experi-
ment. None of the dogs showed any signs of allergic
sensitization, further confirming that our protocol did
not sensitize dogs against peanut. In a study designed
to determine the minimum dose of peanut protein
capable of eliciting an allergic reaction in sensitized
individuals, clinical signs were evident after ingestion of
2000 μg of peanut [56, 60]. Administration of peanut
during the oral food challenge lasted 7 days for 3 dogs
because they were already included in a new experi-
ment which did not allow peanut administration. It has
been reported that the OFC should be continued for 7-
14 days [61–64] because a small percentage of allergic
dogs may require more days to show clinical signs after
being fed the culprit protein. It is unclear, in dogs, if
these delayed reactions require the OFC to be carried
out over several days or if it is enough to administer a
weight-appropriate dose of protein in a single day, as it
is routinely done in human medicine, followed by moni-
toring the patient the following 14 days, as we meticu-
lously did in this experiment.
Conclusions
To conclude, we demonstrated that sublingual adminis-
tration of escalating doses of peanut extract in healthy
dogs is a safe and well tolerated protocol. Given the
premises, this food-specific SLIT protocol might be a
suitable treatment to desensitize dogs with food allergy.
Future research should focus on testing the same protocol
in dogs with proven food allergy.
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